StockData
Reviva Pharmaceuticals Holdings, Inc. logo

Reviva Pharmaceuticals Holdings, Inc. (RVPH) stock

RVPHOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 2/30
$0.45−0.02 (-4.36%)

Close on Oct 19, 2026Market cap $5.94MP/E –Yield –

Reviva Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Reviva Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $5.77M, down 60.6% year over year. For fiscal 2025 it was $11.71M, down 48.9% from the year before. The highest annual figure on record is $31.42M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$11.71M-48.9%
FY2024Dec 31, 2024$22.91M-27.1%
FY2023Dec 31, 2023$31.42M+37.4%
FY2022Dec 31, 2022$22.87M+371.4%
FY2021Dec 31, 2021$4.85M+1543.8%
FY2020Dec 31, 2020$295.15K+50.8%
FY2019Dec 31, 2019$195.74K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.20M-43.8%
Q2 FY2026Jun 30, 2026$1.39M-62.6%
Q1 FY2026Mar 31, 2026$1.44M-65.1%
Q4 FY2025Dec 31, 2025$1.74M-62.8%
Q3 FY2025Sep 30, 2025$2.13M-68.9%
Q2 FY2025Jun 30, 2025$3.72M-33.3%
Q1 FY2025Mar 31, 2025$4.11M-28.9%
Q4 FY2024Dec 31, 2024$4.68M-42.3%
Q3 FY2024Sep 30, 2024$6.86M-28.4%
Q2 FY2024Jun 30, 2024$5.58M-32.4%
Q1 FY2024Mar 31, 2024$5.78M+5.5%
Q4 FY2023Dec 31, 2023$8.11M+9.3%
Q3 FY2023Sep 30, 2023$9.57M+125.7%
Q2 FY2023Jun 30, 2023$8.26M+82.9%
Q1 FY2023Mar 31, 2023$5.48M-5.9%
Q4 FY2022Dec 31, 2022$7.42M+178.5%
Q3 FY2022Sep 30, 2022$4.24M+198.0%
Q2 FY2022Jun 30, 2022$4.51M+1106.0%
Q1 FY2022Mar 31, 2022$5.83M+1390.4%
Q4 FY2021Dec 31, 2021$2.66M–
Q3 FY2021Sep 30, 2021$1.42M–
Q2 FY2021Jun 30, 2021$374.33K–
Q1 FY2021Mar 31, 2021$391.16K–

More Reviva Pharmaceuticals figures

See a number that looks wrong?